Skip to content

Study · Randomized controlled trial · n = 27 · 1994

7 results

Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome.

West CP, Hillier H

Human reproduction (Oxford, England)1 Jun 1994Cited by 26 (Europe PMC)

PMID7962376 (opens in a new tab)DOI10.1093/oxfordjournals.humrep.a138633 (opens in a new tab)PepBankPUB-07962376
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with severe premenstrual tension, cyclical anxiety differences disappeared in a significantly greater proportion of goserelin-treated cycles than placebo cycles.

    In plain wordsIn women with severe premenstrual tension, cyclical anxiety differences disappeared more often with goserelin than placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseCyclical anxiety differences abolished
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Analysis by cycle phase showed that for individual subjects, pre-treatment differences in VAS scores for anxiety and depression were abolished in a significantly greater proportion of actively treated cycles.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with severe premenstrual tension, cyclical depression differences disappeared in a significantly greater proportion of goserelin-treated cycles than placebo cycles.

    In plain wordsIn women with severe premenstrual tension, cyclical depression differences disappeared more often with goserelin than placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseCyclical depression differences abolished
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Analysis by cycle phase showed that for individual subjects, pre-treatment differences in VAS scores for anxiety and depression were abolished in a significantly greater proportion of actively treated cycles.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with severe premenstrual tension, anxiety differed significantly between goserelin and placebo only during treatment cycle 1 and the first post-treatment cycle.

    In plain wordsIn women with severe premenstrual tension, anxiety differed between goserelin and placebo only in the first treatment and first post-treatment cycles.

    Peptide
    Goserelin
    Outcome
    Direction not reportedAnxiety between groups
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Within-group comparisons showed a marked placebo effect and, comparing the two groups, differences reached significance only during treatment cycle 1 and the first post-treatment cycle for anxiety with no significant differences for depression.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with severe premenstrual tension, depression did not differ significantly between goserelin and placebo.

    In plain wordsIn women with severe premenstrual tension, depression did not differ significantly between goserelin and placebo.

    Peptide
    Goserelin
    Outcome
    No significant changeDepression between groups
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Within-group comparisons showed a marked placebo effect and, comparing the two groups, differences reached significance only during treatment cycle 1 and the first post-treatment cycle for anxiety with no significant differences for depression.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with severe premenstrual tension, whole-cycle breast discomfort scores significantly decreased during goserelin treatment.

    In plain wordsIn women with severe premenstrual tension, breast discomfort decreased during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseBreast discomfort
    Study

    n = 15

    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Median symptom scores for whole cycles showed a significant reduction of breast discomfort and swelling during active treatment, with no significant improvement in psychological symptoms.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with severe premenstrual tension, whole-cycle swelling scores significantly decreased during goserelin treatment.

    In plain wordsIn women with severe premenstrual tension, swelling decreased during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseSwelling
    Study

    n = 15

    Outcome group
    Premenstrual Symptoms · Reproductive and sexual health
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Median symptom scores for whole cycles showed a significant reduction of breast discomfort and swelling during active treatment, with no significant improvement in psychological symptoms.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with severe premenstrual tension, whole-cycle psychological symptoms did not significantly improve during goserelin treatment.

    In plain wordsIn women with severe premenstrual tension, psychological symptoms did not significantly improve during goserelin treatment.

    Peptide
    Goserelin
    Outcome
    No significant changeWhole-cycle psychological symptoms
    Study

    n = 15

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg monthly · subcutaneous injection · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Median symptom scores for whole cycles showed a significant reduction of breast discomfort and swelling during active treatment, with no significant improvement in psychological symptoms.
    3 context sentences
    Summary · context
    The objective of this study was to determine the effectiveness of ovarian suppression by a GnRH agonist analogue in 32 women with prospectively confirmed severe premenstrual tension.
    Summary · context
    The design was a randomized, double-blind study comparing goserelin 3.6 mg with placebo, both given as a monthly s.c. injection for 3 months.
    Summary · context
    Of the 16 women in each group, 15 completed active and 12 completed placebo therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.